

Proxy Voting Record

Next Edge Biotech and Life Sciences Opportunities Fund

For the period of July 1, 2024 to June 30, 2025



Next Edge Capital Corp.

18 King St., Suite 902

Toronto, ON M5C 1C4

(416) 775-3600

www.nextedgecapital.com

Proxy Voting Record

Proxy Voting Report: Q3 2024

Next Edge Biotech and Life Sciences Opportunities Fund

For the period of July 1, 2024 to September 30, 2024

Vote Summary

NEURAXIS, INC.

Security	64134X201	Meeting Type	Annual
Ticker Symbol	NRXS	Meeting Date	15-Aug-2024
ISIN	US64134X2018	Agenda	936109405 - Management
Record Date	17-Jun-2024	Holding Recon Date	17-Jun-2024
City / Country	/ United States	Vote Deadline	14-Aug-2024 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Brian Carrico		For	For
	2 Dr. Christopher R Brown		For	For
	3 Bradley Mitch Watkins		For	For
	4 Beth Keyser		For	For
	5 Kristin Ferge		For	For
2.	The ratification of the appointment of Rosenberg Rich Baker Berman, P.A. as our independent registered public accounting firm for the fiscal year ending December 31, 2024.	Management	For	For
3.	The approval of the amendment to Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan to increase the number of shares available for issuance by 300,000 shares and to insert an "evergreen" provision that allows for an annual increase in the number of shares available for issuance under the 2022 Plan to be added on the first day of each fiscal year through and including 2031 in an amount equal to 5% of the number of shares of our common stock outstanding on the immediately preceding December 31 or such lesser amount determined by our Board.	Management	For	For
4.	The approval of the amendment to the Certificate of Incorporation to authorize the "blank check" preferred stock that could be issued by the Board.	Management	For	For
5.	The approval of the issuance of 20% or more of the outstanding shares of Common Stock, upon the conversion of the Series B Preferred Stock, into up to 3,838,235 shares of Common Stock, in accordance with NYSE American Rule 713(a).	Management	For	For
6.	The approval, on an advisory basis, of the compensation paid to our named executive officers.	Management	For	For
7.	The approval, on an advisory basis, of the frequency of three (3) years for future shareholder advisory votes on the compensation of our named executive officers.	Management	3 Years	For

Vote Summary

8.	The approval of the adjournment of the Annual Meeting, if necessary or advisable, to solicit additional proxies in favor of the foregoing proposals if there are not sufficient votes to approve the foregoing proposals.	Management	For	For
----	---	------------	-----	-----

Vote Summary

UROGEN PHARMA LTD

Security	M96088105	Meeting Type	Annual
Ticker Symbol	URGN	Meeting Date	06-Aug-2024
ISIN	IL0011407140	Agenda	936115004 - Management
Record Date	28-Jun-2024	Holding Recon Date	28-Jun-2024
City / Country	/ United States	Vote Deadline	05-Aug-2024 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director to hold office until the Company's next annual meeting of shareholders: Arie Beldegrun	Management	For	For
1b.	Election of Director to hold office until the Company's next annual meeting of shareholders: Elizabeth Barrett	Management	For	For
1c.	Election of Director to hold office until the Company's next annual meeting of shareholders: Cynthia M. Butitta	Management	For	For
1d.	Election of Director to hold office until the Company's next annual meeting of shareholders: Fred E. Cohen	Management	For	For
1e.	Election of Director to hold office until the Company's next annual meeting of shareholders: Stuart Holden	Management	For	For
1f.	Election of Director to hold office until the Company's next annual meeting of shareholders: James A. Robinson, Jr.	Management	For	For
1g.	Election of Director to hold office until the Company's next annual meeting of shareholders: Leana S. Wen	Management	For	For
1h.	Election of Director to hold office until the Company's next annual meeting of shareholders: Daniel G. Wildman	Management	For	For
2.	To approve the Company's 2024 non-employee director and officer compensation policy.	Management	For	For
3.	To approve an amendment to the Company's 2017 Equity Incentive Plan to increase the number of ordinary shares authorized for issuance under the plan by 800,000 shares.	Management	For	For
4.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.	Management	For	For
5.	To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the Company's auditor until the Company's 2025 annual meeting of shareholders.	Management	For	For

Proxy Voting Record

Proxy Voting Report: Q4 2024

Next Edge Biotech and Life Sciences Opportunities Fund

For the period of October 1, 2024 to December 31, 2024

Vote Summary

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Security	76152G100	Meeting Type	Annual
Ticker Symbol	RVPH	Meeting Date	10-Dec-2024
ISIN	US76152G1004	Agenda	936155274 - Management
Record Date	14-Oct-2024	Holding Recon Date	14-Oct-2024
City / Country	/ United States	Vote Deadline	09-Dec-2024 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Laxminarayan Bhat		For	For
	2 Parag Saxena		For	For
	3 Richard Margolin		For	For
	4 Purav Patel		For	For
	5 Les Funtleyder		For	For
2.	Ratification of the appointment of Moss Adams LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.	Management	For	For
3.	To approve, on an advisory basis, the executive compensation of the Company's named executive officers as described in the proxy statement.	Management	For	For
4.	To vote, on an advisory basis, on how often the Company will conduct an advisory vote on executive compensation.	Management	1 Year	For
5.	To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the Company's authorized shares of common stock from 115,000,000 to 315,000,000 ("Proposal 5").	Management	For	For
6.	To approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies in the event that the number of shares of common stock present or represented by proxy at the Annual Meeting and voting "FOR" the adoption of Proposal 5 are insufficient to approve Proposal 5.	Management	For	For

Vote Summary

TAO SYNERGIES				
Security	87167T300		Meeting Type	Annual
Ticker Symbol	SNPX		Meeting Date	06-Dec-2024
ISIN	US87167T3005		Agenda	936165489 - Management
Record Date	05-Nov-2024		Holding Recon Date	05-Nov-2024
City / Country	/ United States		Vote Deadline	05-Dec-2024 11:59 PM ET
SEDOL(s)			Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Joshua N. Silverman		For	For
	2 William S. Singer		For	For
2.	To authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying shares of convertible preferred stock and warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement, dated 9/10/2024, by and among Synaptogenix, Inc. and the investors named therein, in an amount equal to or in excess of 20% of our common stock outstanding before the issuance of such convertible preferred stock and warrants.	Management	For	For
3.	To approve a proposed amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan to, among other things, increase the number of shares available for the grant of awards by 500,000 shares.	Management	Against	Against
4.	To ratify the appointment of Stephano Slack LLC as our independent registered public accounting firm for the fiscal year ending December 31, 2024.	Management	For	For

Vote Summary

INHIBIKASE THERAPEUTICS, INC.			
Security	45719W205	Meeting Type	Special
Ticker Symbol	IKT	Meeting Date	03-Jan-2025
ISIN	US45719W2052	Agenda	936164401 - Management
Record Date	11-Nov-2024	Holding Recon Date	11-Nov-2024
City / Country	/ United States	Vote Deadline	02-Jan-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To approve an amendment to Section 1 of Article IV of our Amended and Restated Certificate of Incorporation to increase the number of our authorized shares of common stock from 100,000,000 shares to 500,000,000 shares.	Management	For	For
2.	To approve an amendment to our 2020 Equity Incentive Plan to increase the number of authorized shares of common stock reserved for issuance by 27,453,993 shares.	Management	For	For
3.	To approve the repricing of certain outstanding stock options.	Management	For	For
4.	To approve an amendment to Article XII of our Amended and Restated Certificate of Incorporation to eliminate the 66 2/3% affirmative vote requirement for amendments to Section 1 of Article IV thereof.	Management	For	For

Vote Summary

SIMULATIONS PLUS, INC.			
Security	829214105	Meeting Type	Annual
Ticker Symbol	SLP	Meeting Date	13-Feb-2025
ISIN	US8292141053	Agenda	936174957 - Management
Record Date	17-Dec-2024	Holding Recon Date	17-Dec-2024
City / Country	/ United States	Vote Deadline	12-Feb-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Dr. Daniel Weiner		For	For
	2 Dr. Walter S. Woltosz		For	For
	3 Dr. John K. Paglia		For	For
	4 Dr. Lisa LaVange		For	For
	5 Sharlene Evans		For	For
2.	Ratification of the selection of Rose, Snyder & Jacobs LLP as the independent registered public accounting firm for the Company for the fiscal year ending August 31, 2025.	Management	For	For
3.	Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers.	Management	For	For

Proxy Voting Record

Proxy Voting Report: Q1 2025

Next Edge Biotech and Life Sciences Opportunities Fund

For the period of January 1, 2025 to March 31, 2025

Vote Summary

MICROBIX BIOSYSTEMS INC.				
Security	59501P104	Meeting Type	Annual and Special Meeting	
Ticker Symbol	MBXBF	Meeting Date	26-Mar-2025	
ISIN	CA59501P1045	Agenda	936189530 - Management	
Record Date	07-Feb-2025	Holding Recon Date	07-Feb-2025	
City / Country	/ Canada		Vote Deadline	21-Mar-2025 11:59 PM ET
SEDOL(s)	Quick Code			

Item	Proposal	Proposed by	Vote	For/Against Management
1	DIRECTOR	Management		
	1 Peter M. Blecher		Withheld	Against
	2 Mark A. Cochran		Withheld	Against
	3 V. C. Embro-Pantalony		For	For
	4 Joseph D. Renner		For	For
	5 Martin Marino		Withheld	Against
	6 Cameron Groome		For	For
	7 Jennifer Stewart		Withheld	Against
2	Appointment of Ernst & Young LLP as Auditors of the Company.	Management	For	For

Vote Summary

CLENE INC.

Security	185634201	Meeting Type	Annual
Ticker Symbol	CLNN	Meeting Date	22-May-2025
ISIN	US1856342019	Agenda	936233561 - Management
Record Date	25-Mar-2025	Holding Recon Date	25-Mar-2025
City / Country	/ United States	Vote Deadline	21-May-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 David J. Matlin		For	For
	2 Arjun "JJ" Desai, M.D.		For	For
	3 Matthew K. AM Ph.D DSc		For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2025.	Management	For	For
3.	Approval, on an advisory basis, of the compensation of our Named Executive Officers.	Management	For	For
4.	Approval of an amendment to the Clene Inc. Amended 2020 Stock Plan to increase the number of shares of Common Stock reserved for issuance thereunder by 800,000 shares.	Management	For	For

Vote Summary

NEURAXIS, INC.

Security	64134X201	Meeting Type	Annual
Ticker Symbol	NRXS	Meeting Date	29-May-2025
ISIN	US64134X2018	Agenda	936239284 - Management
Record Date	31-Mar-2025	Holding Recon Date	31-Mar-2025
City / Country	/ United States	Vote Deadline	28-May-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Beth Keyser		For	For
	2 Bradley Mitch Watkins		For	For
	3 Kristin Ferge		For	For
	4 Gilad Aharon		For	For
	5 Brian Carrico		For	For
	6 Christopher Robin Brown		For	For
2.	To ratify the appointment of Rosenberg Rich Baker Berman, P.A. as our independent registered public accounting firm for the fiscal year ending December 31, 2025.	Management	For	For
3.	To approve, for purposes of NYSE American Rule 713(a), the issuance of 20% or more of the outstanding shares of the Company's Common Stock, par value \$0.001 (the "Common Stock") upon the conversion of the Company's Series B Convertible Preferred Stock, par value \$0.001 per share (the "Series B Preferred Stock") into up to 2,031,804 shares of Common Stock.	Management	For	For

Proxy Voting Record

Proxy Voting Report: Q2 2025

Next Edge Biotech and Life Sciences Opportunities Fund

For the period of April 1, 2025 to June 30, 2025

Vote Summary

ESPERION THERAPEUTICS, INC.				
Security	29664W105		Meeting Type	Annual
Ticker Symbol	ESPR		Meeting Date	29-May-2025
ISIN	US29664W1053		Agenda	936240011 - Management
Record Date	01-Apr-2025		Holding Recon Date	01-Apr-2025
City / Country	/ United States		Vote Deadline	28-May-2025 11:59 PM ET
SEDOL(s)			Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class III Director: Jay P. Shepard	Management	For	For
1b.	Election of Class III Director: Seth H.Z. Fischer	Management	For	For
2.	To approve the non-binding advisory resolution on the compensation of our named executive officers.	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.	Management	For	For
4.	To approve an amendment to the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan.	Management	For	For

Vote Summary

TAYSHA GENE THERAPIES, INC.				
Security	877619106	Meeting Type	Annual	
Ticker Symbol	TSHA	Meeting Date	02-Jun-2025	
ISIN	US8776191061	Agenda	936248310 - Management	
Record Date	03-Apr-2025	Holding Recon Date	03-Apr-2025	
City / Country	/ United States	Vote Deadline	30-May-2025 11:59 PM ET	
SEDOL(s)		Quick Code		
Item	Proposal	Proposed by	Vote	For/Against Management

1.	DIRECTOR	Management		
	1 Phillip B Donenberg CPA		For	For
	2 Sukumar Nagendran, MD		For	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2025.	Management	For	For
3.	To approve a proposed amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of common stock from 400,000,000 to 700,000,000 shares.	Management	For	For

Vote Summary

NEKTAR THERAPEUTICS

Security	640268108	Meeting Type	Annual
Ticker Symbol	NKTR	Meeting Date	23-May-2025
ISIN	US6402681083	Agenda	936270773 - Management
Record Date	07-Apr-2025	Holding Recon Date	07-Apr-2025
City / Country	/ United States	Vote Deadline	22-May-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Diana Brainard	Management	For	For
1b.	Election of Director: R. Scott Greer	Management	For	For
2.	To approve an amendment to our Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,000,000 shares.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.	Management	For	For
4.	To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).	Management	For	For
5.	To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from 300,000,000 shares to 390,000,000 shares.	Management	For	For
6.	To approve an amendment to our Certificate of Incorporation to effect, at the discretion of our board of directors on or prior to the one-year anniversary of the date of the Annual Meeting, a reverse stock split of our common stock at a stock split ratio between 1-for-2 and 1-for-40, with the final ratio to be determined by the board of directors in its sole discretion, the implementation and timing of which shall be subject to the sole discretion of the board of directors.	Management	For	For

Vote Summary

STOKE THERAPEUTICS, INC.

Security	86150R107	Meeting Type	Annual
Ticker Symbol	STOK	Meeting Date	03-Jun-2025
ISIN	US86150R1077	Agenda	936252903 - Management
Record Date	07-Apr-2025	Holding Recon Date	07-Apr-2025
City / Country	/ United States	Vote Deadline	02-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Edward M. Kaye, M.D.		For	For
	2 Seth L. Harrison, M.D.		For	For
	3 A. O. Tzianabos, Ph.D.		For	For
2.	To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's named executive officers.	Management	For	For
4.	To indicate, on an advisory basis, the preferred frequency of future stockholder advisory votes to approve the compensation of the Company's named executive officers.	Management	1 Year	For

Vote Summary

10X GENOMICS, INC.

Security	88025U109	Meeting Type	Annual
Ticker Symbol	TXG	Meeting Date	03-Jun-2025
ISIN	US88025U1097	Agenda	936260001 - Management
Record Date	08-Apr-2025	Holding Recon Date	08-Apr-2025
City / Country	/ United States	Vote Deadline	02-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class III Director to serve a three-year term expiring at the 2028 annual meeting of stockholders or until such director's successors are duly elected and qualified or until such director's earlier death, resignation, disqualification or removal: Sri Kosaraju	Management	For	For
1.2	Election of Class III Director to serve a three-year term expiring at the 2028 annual meeting of stockholders or until such director's successors are duly elected and qualified or until such director's earlier death, resignation, disqualification or removal: Shehnaaz Suliman	Management	For	For
2.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.	Management	For	For
3.	To approve, on a non-binding, advisory basis, the compensation of our named executive officers.	Management	For	For

Vote Summary

SANA BIOTECHNOLOGY, INC.

Security	799566104	Meeting Type	Annual
Ticker Symbol	SANA	Meeting Date	05-Jun-2025
ISIN	US7995661045	Agenda	936259628 - Management
Record Date	07-Apr-2025	Holding Recon Date	07-Apr-2025
City / Country	/ United States	Vote Deadline	04-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class I Director to serve for a three-year term expiring at the 2028 annual meeting of stockholders or until his or her respective successor is duly elected and qualified: Steven D. Harr, M.D.	Management	For	For
1.2	Election of Class I Director to serve for a three-year term expiring at the 2028 annual meeting of stockholders or until his or her respective successor is duly elected and qualified: Robert L. Rosiello	Management	For	For
1.3	Election of Class I Director to serve for a three-year term expiring at the 2028 annual meeting of stockholders or until his or her respective successor is duly elected and qualified: Michelle Seitz, CFA	Management	For	For
1.4	Election of Class I Director to serve for a three-year term expiring at the 2028 annual meeting of stockholders or until his or her respective successor is duly elected and qualified: Patrick Y. Yang, Ph.D.	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.	Management	For	For

Vote Summary

ACUMEN PHARMACEUTICALS, INC.

Security	00509G209	Meeting Type	Annual
Ticker Symbol	ABOS	Meeting Date	04-Jun-2025
ISIN	US00509G2093	Agenda	936258551 - Management
Record Date	08-Apr-2025	Holding Recon Date	08-Apr-2025
City / Country	/ United States	Vote Deadline	03-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class I Director to hold office until the 2028 Annual Meeting of Stockholders, and until his or her successor shall have been duly elected and qualified: Kimberlee C. Drapkin	Management	For	For
1.2	Election of Class I Director to hold office until the 2028 Annual Meeting of Stockholders, and until his or her successor shall have been duly elected and qualified: Jeffrey Ives, Ph.D.	Management	For	For
1.3	Election of Class I Director to hold office until the 2028 Annual Meeting of Stockholders, and until his or her successor shall have been duly elected and qualified: Sean Stalfort	Management	For	For
2.	To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.	Management	For	For

Vote Summary

ANNEXON, INC.				
Security	03589W102		Meeting Type	Annual
Ticker Symbol	ANNX		Meeting Date	05-Jun-2025
ISIN	US03589W1027		Agenda	936255430 - Management
Record Date	08-Apr-2025		Holding Recon Date	08-Apr-2025
City / Country	/ United States		Vote Deadline	04-Jun-2025 11:59 PM ET
SEDOL(s)			Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Jung E. Choi		For	For
	2 William D. Waddill		For	For
2.	To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.	Management	For	For

Vote Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.			
Security	69404D108	Meeting Type	Annual
Ticker Symbol	PACB	Meeting Date	04-Jun-2025
ISIN	US69404D1081	Agenda	936251052 - Management
Record Date	10-Apr-2025	Holding Recon Date	10-Apr-2025
City / Country	/ United States	Vote Deadline	03-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: William Ericson	Management	For	For
1b.	Election of Director: Kathy Ordoñez	Management	For	For
1c.	Election of Director: Christopher M. Smith	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025.	Management	For	For
3.	To approve, on an advisory basis, the compensation of our named executive officers.	Management	For	For
4.	To approve the amendment of our 2020 Equity Incentive Plan.	Management	For	For

Vote Summary

XERIS BIOPHARMA HOLDINGS, INC.

Security	98422E103	Meeting Type	Annual
Ticker Symbol	XERS	Meeting Date	04-Jun-2025
ISIN	US98422E1038	Agenda	936259832 - Management
Record Date	14-Apr-2025	Holding Recon Date	14-Apr-2025
City / Country	/ United States	Vote Deadline	03-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class I Director to serve until the 2028 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: BJ Bormann	Management	For	For
1.2	Election of Class I Director to serve until the 2028 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: James Brady	Management	For	For
1.3	Election of Class I Director to serve until the 2028 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Garheng Kong	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of our named executive officers.	Management	For	For

Vote Summary

OCUGEN, INC.				
Security	67577C105		Meeting Type	Annual
Ticker Symbol	OCGN		Meeting Date	05-Jun-2025
ISIN	US67577C1053		Agenda	936265532 - Management
Record Date	14-Apr-2025		Holding Recon Date	14-Apr-2025
City / Country	/ United States		Vote Deadline	04-Jun-2025 11:59 PM ET
SEDOL(s)			Quick Code	
Item	Proposal	Proposed by	Vote	For/Against Management

1.	DIRECTOR	Management		
	1 Uday Kompella, Ph.D.		For	For
	2 Blaise Coleman		For	For
	3 Satish Chandran, Ph.D.		For	For
2.	Ratification of Appointment of PricewaterhouseCoopers LLP as Ocugen, Inc.'s Independent Registered Public Accounting Firm for 2025.	Management	For	For
3.	Approval, on an advisory basis, of the compensation of Ocugen, Inc.'s named executive officers.	Management	For	For

Vote Summary

TG THERAPEUTICS, INC.

Security	88322Q108	Meeting Type	Annual
Ticker Symbol	TGTX	Meeting Date	12-Jun-2025
ISIN	US88322Q1085	Agenda	936263223 - Management
Record Date	14-Apr-2025	Holding Recon Date	14-Apr-2025
City / Country	/ United States	Vote Deadline	11-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Laurence Charney		For	For
	2 Yann Echelard		For	For
	3 Kenneth Hoberman		For	For
	4 Daniel Hume		For	For
	5 Sagar Lonial, MD		For	For
	6 Michael S. Weiss		For	For
2.	To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2025.	Management	For	For
3.	An advisory vote to approve the compensation of our named executive officers.	Management	For	For
4.	To approve Amendment No. 2 to our 2022 Incentive Plan to increase the number of shares of common stock authorized for issuance under the 2022 Incentive Plan from 17,000,000 to 22,000,000 shares.	Management	For	For

Vote Summary

ACHIEVE LIFE SCIENCES INC.

Security	004468500	Meeting Type	Annual
Ticker Symbol	ACHV	Meeting Date	04-Jun-2025
ISIN	US0044685008	Agenda	936273642 - Management
Record Date	15-Apr-2025	Holding Recon Date	15-Apr-2025
City / Country	/ United States	Vote Deadline	03-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Stuart Duty		For	For
	2 Bridget Martell		For	For
	3 Thomas B. King		For	For
	4 Thomas Sellig		For	For
	5 Richard Stewart		For	For
	6 Nancy R. Phelan		For	For
	7 Kristen Slaoui		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.	Management	For	For
3.	To approve an amendment to our 2023 Non-Employee Director Equity Incentive Plan to increase the number of shares available for issuance thereunder.	Management	For	For

Vote Summary

CRISPR THERAPEUTICS AG

Security	H17182108	Meeting Type	Annual
Ticker Symbol	CRSP	Meeting Date	05-Jun-2025
ISIN	CH0334081137	Agenda	936257509 - Management
Record Date	15-Apr-2025	Holding Recon Date	15-Apr-2025
City / Country	/ Switzerland	Vote Deadline	04-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2024.	Management	For	For
2.	Approval of the appropriation of financial results.	Management	For	For
3.	Discharge of the members of the Board of Directors and the Executive Committee.	Management	For	For
4a.	Re-election of Samarth Kulkarni, Ph.D., as member and Chairman	Management	For	For
4b.	Re-election of Ali Behbahani, M.D.	Management	For	For
4c.	Re-election of Maria Fardis, Ph.D.	Management	For	For
4d.	Re-election of H. Edward Fleming, Jr., M.D.	Management	For	For
4e.	Re-election of Simeon J. George, M.D.	Management	For	For
4f.	Re-election of John T. Greene	Management	For	For
4g.	Re-election of Katherine A. High, M.D.	Management	For	For
4h.	Re-election of Sandesh Mahatme, LL.M.	Management	For	For
4i.	Re-election of Christian Rommel, Ph.D.	Management	For	For
4j.	Re-election of Douglas A. Treco, Ph.D.	Management	For	For
4k.	Election of Briggs W. Morrison, M.D.	Management	For	For
5a.	Re-election of the member of the Compensation Committee: Ali Behbahani, M.D.	Management	For	For
5b.	Re-election of the member of the Compensation Committee: H. Edward Fleming, Jr., M.D.	Management	For	For
5c.	Re-election of the member of the Compensation Committee: John T. Greene	Management	For	For
5d.	Election of the member of the Compensation Committee: Briggs W. Morrison, M.D.	Management	For	For
6a.	Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders.	Management	For	For

Vote Summary

6b.	Binding vote on maximum equity for members of the Board of Directors from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders.	Management	For	For
6c.	Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2025 to June 30, 2026.	Management	For	For
6d.	Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2025.	Management	For	For
6e.	Binding vote on maximum equity for members of the Executive Committee from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders.	Management	For	For
6f.	Non-binding advisory vote on the 2024 Compensation Report.	Management	For	For
7.	Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securities law requirements.	Management	For	For
8.	Approval of increasing the maximum size of the Board of Directors.	Management	For	For
9.	Re-election of the independent voting rights representative.	Management	For	For
10.	Re-election of the auditors.	Management	For	For
11.	Transact any other business that may properly come before the 2025 Annual General Meeting or any adjournment or postponement thereof.	Management	For	For

Vote Summary

ALECTOR, INC.			
Security	014442107	Meeting Type	Annual
Ticker Symbol	ALEC	Meeting Date	11-Jun-2025
ISIN	US0144421072	Agenda	936257636 - Management
Record Date	15-Apr-2025	Holding Recon Date	15-Apr-2025
City / Country	/ United States	Vote Deadline	10-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Arnon Rosenthal, Ph.D.		For	For
	2 Paula Hammond, Ph.D.		For	For
2.	Ratification of the appointment of Ernst & Young, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.	Management	For	For
3.	Advisory vote on executive compensation.	Management	For	For

Vote Summary

CULLINAN THERAPEUTICS, INC.				
Security	230031106		Meeting Type	Annual
Ticker Symbol	CGEM		Meeting Date	12-Jun-2025
ISIN	US2300311063		Agenda	936259565 - Management
Record Date	15-Apr-2025		Holding Recon Date	15-Apr-2025
City / Country	/ United States		Vote Deadline	11-Jun-2025 11:59 PM ET
SEDOL(s)			Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Anthony Rosenberg		For	For
	2 David P. Ryan, M.D.		For	For
	3 Mary Thistle		For	For
2.	Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2025.	Management	For	For
3.	Proposal to vote, on an advisory basis, to approve our named executive officer compensation.	Management	For	For
4.	Proposal to vote, on an advisory basis, on the frequency of future advisory votes on our named executive officer compensation.	Management	1 Year	For

Vote Summary

LONGEVERON INC.				
Security	54303L203	Meeting Type	Annual	
Ticker Symbol	LGVN	Meeting Date	13-Jun-2025	
ISIN	US54303L2034	Agenda	936269592 - Management	
Record Date	21-Apr-2025	Holding Recon Date	21-Apr-2025	
City / Country	/ United States	Vote Deadline	12-Jun-2025 11:59 PM ET	
SEDOL(s)		Quick Code		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Rock Soffer	Management	For	For
2.	Approval of an amendment to the Second Amended and Restated Longeveron Inc. 2021 Incentive Award Plan	Management	For	For
3.	Ratification of the appointment of CBIZ CPAs P.C. as Longeveron's independent registered public accounting firm for the year ending December 31, 2025	Management	For	For

Vote Summary

FORTRESS BIOTECH, INC.

Security	34960Q307	Meeting Type	Annual
Ticker Symbol	FBIO	Meeting Date	17-Jun-2025
ISIN	US34960Q3074	Agenda	936270709 - Management
Record Date	21-Apr-2025	Holding Recon Date	21-Apr-2025
City / Country	/ United States	Vote Deadline	16-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Lindsay A. Rosenwald, M.D.	Management	For	For
1b.	Election of Director: Michael S. Weiss	Management	For	For
1c.	Election of Director: Jimmie Harvey, Jr., M.D.	Management	For	For
1d.	Election of Director: Malcolm Hoenlein	Management	For	For
1e.	Election of Director: Dov Klein, CPA	Management	For	For
1f.	Election of Director: J. Jay Lobell	Management	For	For
1g.	Election of Director: Kevin L. Lorenz, J.D.	Management	For	For
2.	Ratification of the appointment of KPMG LLP as Fortress Biotech, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2025.	Management	For	For
3.	The approval, on an advisory basis, of the compensation of the Company's named executive officers.	Management	For	For
4.	The approval, on an advisory basis, of the frequency of our non-binding advisory votes approving the compensation of the named executive officers of the Company.	Management	3 Years	For
5.	The approval of the Second Amended and Restated Certificate of Incorporation of the Company to provide for, among other things, officer exculpation.	Management	For	For

Vote Summary

COGNITION THERAPEUTICS, INC.				
Security	19243B102		Meeting Type	Annual
Ticker Symbol	CGTX		Meeting Date	18-Jun-2025
ISIN	US19243B1026		Agenda	936265051 - Management
Record Date	21-Apr-2025		Holding Recon Date	21-Apr-2025
City / Country	/ United States		Vote Deadline	17-Jun-2025 11:59 PM ET
SEDOL(s)			Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Peggy Wallace		For	For
	2 Ellen B. Richstone		For	For
2.	Ratification of Appointment of Ernst & Young LLP as the company's Independent Registered Public Accounting Firm for 2025.	Management	For	For

Vote Summary

ALPHA COGNITION INC.

Security	02074J501	Meeting Type	Annual
Ticker Symbol	ACOG	Meeting Date	19-Jun-2025
ISIN	CA02074J5017	Agenda	936286980 - Management
Record Date	22-Apr-2025	Holding Recon Date	22-Apr-2025
City / Country	/ Canada	Vote Deadline	16-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1	To set the number of Directors at six (6).	Management	For	For
2	DIRECTOR	Management		
	1 Michael McFadden		For	For
	2 Kenneth Cawkell		For	For
	3 Rajeev 'Rob' Bakshi		For	For
	4 Len Mertz		For	For
	5 Phillip Mertz		For	For
	6 Robert Wills		For	For
3	Appointment of Manning Elliott LLP as auditors of the Company for the ensuing year and authorizing the directors to fix their remuneration.	Management	For	For
4	To consider and, if thought advisable, to pass, with or without variation, an ordinary resolution ratifying, confirming and approving the adoption of the Company's 2025 Stock and Incentive Plan.	Management	For	For

Vote Summary

RENOVORX, INC.

Security	75989R107	Meeting Type	Annual
Ticker Symbol	RNXT	Meeting Date	24-Jun-2025
ISIN	US75989R1077	Agenda	936282324 - Management
Record Date	25-Apr-2025	Holding Recon Date	25-Apr-2025
City / Country	/ United States	Vote Deadline	23-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Shaun R. Bagai		For	For
	2 Ramtin Agah, M.D.		For	For
	3 Kirsten A. Macfarlane		For	For
	4 Laurence J. Marton MD		For	For
	5 Una S Ryan OBE PhD DSc		For	For
	6 R. J. Spiegel MD FACP		For	For
2.	To approve two amendments to the Company's Amended and Restated 2021 Omnibus Equity Incentive Plan, specifically (i) the addition of 913,794 shares of common stock of the Company, which is equal to 2.5% of total issued and outstanding shares, to the shares of common stock reserved and available for issuance thereunder and (ii) an increase in the 2021 Plan's "evergreen" provision to increase the size of the 2021 Plan each year from three percent (3%) of shares outstanding on the final day of the immediately preceding calendar year to five percent (5%).	Management	For	For
3.	To ratify the appointment by the Board's audit committee of Frank, Rimerman + Co. LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.	Management	For	For

Vote Summary

CALCIMEDICA, INC.

Security	38942Q202	Meeting Type	Annual
Ticker Symbol	CALC	Meeting Date	24-Jun-2025
ISIN	US38942Q2021	Agenda	936273983 - Management
Record Date	28-Apr-2025	Holding Recon Date	28-Apr-2025
City / Country	/ United States	Vote Deadline	23-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director to serve a three-year term through the 2028 annual meeting of stockholders following the 2025 annual meeting of stockholders and until a successor has been elected and qualified or until earlier resignation or removal: A. Rachel Leheny, Ph.D.	Management	For	For
1.2	Election of Class II Director to serve a three-year term through the 2028 annual meeting of stockholders following the 2025 annual meeting of stockholders and until a successor has been elected and qualified or until earlier resignation or removal: Eric W. Roberts	Management	For	For
1.3	Election of Class II Director to serve a three-year term through the 2028 annual meeting of stockholders following the 2025 annual meeting of stockholders and until a successor has been elected and qualified or until earlier resignation or removal: Frederic Guerard, Pharm.D.	Management	For	For
2.	To ratify the appointment of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.	Management	For	For
3.	To approve an amendment to the CalciMedica, Inc. Amended 2023 Equity Incentive Plan, to, among other things, increase the number of shares of our common stock authorized for issuance under the 2023 Plan by 600,000 shares.	Management	For	For

Vote Summary

UNICYCIVE THERAPEUTICS, INC.

Security	90466Y103	Meeting Type	Annual
Ticker Symbol	UNCY	Meeting Date	09-Jun-2025
ISIN	US90466Y1038	Agenda	936278983 - Management
Record Date	30-Apr-2025	Holding Recon Date	30-Apr-2025
City / Country	/ United States	Vote Deadline	06-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Dr. Gaurav Aggarwal	Management	For	For
1.2	Election of Director: Dr. Shalabh Gupta	Management	For	For
1.3	Election of Director: Dr. Sandeep Laumas	Management	For	For
1.4	Election of Director: Dr. Saraswati Kenkare-Mitra	Management	For	For
2.	Proposal to ratify Grassi & Co., CPAs, P.C. as the Company's independent registered public accountants for the fiscal year ending December 31, 2025.	Management	For	For
3.	Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock, at a ratio within the range of 1-for-2 to 1-for-20 (the "Reverse Stock Split"), with the final ratio to be selected by our board of directors in its discretion at any time, if at all, within one year of the date of the Annual Meeting without further approval or authorization of our stockholders.	Management	For	For

Vote Summary

COYA THERAPEUTICS, INC.			
Security	22407B108	Meeting Type	Annual
Ticker Symbol	COYA	Meeting Date	26-Jun-2025
ISIN	US22407B1089	Agenda	936284734 - Management
Record Date	06-May-2025	Holding Recon Date	06-May-2025
City / Country	/ United States	Vote Deadline	25-Jun-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Howard Berman, Ph.D.	Management	For	For
1.2	Election of Director: Arun Swaminathan, Ph.D.	Management	For	For
1.3	Election of Director: Ann Lee, Ph.D.	Management	For	For
2.	Ratify the appointment of Weaver and Tidwell, L.L.P. as the Company's independent public accounting firm for the year ending December 31, 2025	Management	For	For

Vote Summary

NEWAMSTERDAM PHARMA COMPANY N.V.

Security	N62509109	Meeting Type	Annual
Ticker Symbol	NAMS	Meeting Date	04-Jun-2025
ISIN	NL00150012L7	Agenda	936285546 - Management
Record Date	07-May-2025	Holding Recon Date	07-May-2025
City / Country	/ Netherlands	Vote Deadline	30-May-2025 11:59 PM ET
SEDOL(s)		Quick Code	

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2024.	Management	For	For
2.	Discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2024.	Management	For	For
3.	Instruction to Deloitte Accountants B.V. as the Company's external auditor of the Company's Dutch statutory annual accounts and Dutch statutory board report for the fiscal year ending December 31, 2025.	Management	For	For
4.	Ratification of the selection of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 by the audit committee of the Company's Board of Directors.	Management	For	For
5a.	Appointment of Wouter Joustra as non-executive director of the Company until the 2027 annual general meeting.	Management	For	For
5b.	Appointment of Mark McKenna as non-executive director of the Company until the 2028 annual general meeting.	Management	For	For
5c.	Appointment of Adele Gulfo as non-executive director of the Company until the 2029 annual general meeting.	Management	For	For
6a.	Reappointment of Michael Davidson M.D. as executive director of the Company until the 2029 annual general meeting.	Management	For	For
6b.	Reappointment of James N. Topper as non-executive director of the Company until the 2029 annual general meeting.	Management	For	For
7.	Extension of authorization for the Board of Directors to acquire ordinary shares and depository receipts for ordinary shares in the Company's capital.	Management	For	For
8.	Non-binding, advisory vote to approve the 2024 compensation of named executive officers.	Management	For	For
9.	Non-binding, advisory vote regarding frequency of future shareholders' advisory votes on the compensation of named executive officers.	Management	1 Year	For